{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
DexCom, Inc.
Is DexCom, Inc. overvalued or undervalued?
As of October 31, 2025, DexCom, Inc. is fairly valued with a P/E ratio of 64, but has significantly underperformed the S&P 500 with a year-to-date return of -22.30% compared to the index's 16.30%.
DexCom Stock Hits Day Low of $56.45 Amid Price Pressure
DexCom, Inc. faced notable stock volatility on October 31, 2025, with a significant decline. Over the past week and month, the company's performance has weakened, contrasting with the S&P 500. Despite this, DexCom maintains a strong financial profile, including high return on equity and robust sales growth.
DexCom, Inc. Hits New 52-Week Low at $56.45 Amid Market Struggles
DexCom, Inc. has reached a new 52-week low, reflecting a challenging year with a significant decline in stock price. The company, valued at approximately USD 30.66 billion, has a high P/E ratio and does not offer dividends. Its financial metrics indicate a conservative leverage approach and effective management of shareholder equity.
DexCom, Inc. Experiences Valuation Adjustment Amidst Competitive Market Dynamics
DexCom, Inc. has experienced a valuation adjustment, with its stock price declining significantly over the past year. The company reports a P/E ratio of 64 and an EV to EBITDA ratio of 39.43, indicating a premium valuation compared to competitors. Its operational efficiency is highlighted by a ROCE of 31.15% and ROE of 23.61%.
Is DexCom, Inc. overvalued or undervalued?
As of October 31, 2025, DexCom, Inc. is fairly valued with a P/E ratio of 64 and an EV to EBITDA of 39.43, but has underperformed the S&P 500 with a year-to-date return of -25.14%.
Is DexCom, Inc. overvalued or undervalued?
As of October 31, 2025, DexCom, Inc. is fairly valued with a P/E ratio of 64, but has underperformed the S&P 500 with a year-to-date return of -25.14%.
DexCom Adjusts Valuation Grade Amid Strong Financial Performance and Growth Indicators
DexCom, Inc. has recently adjusted its valuation grade, moving from very expensive to expensive. Key financial metrics include a P/E ratio of 64, a price-to-book value of 15.03, and strong returns on capital employed and equity. The company also reports significant long-term growth in net sales and operating profit.
Is DexCom, Inc. overvalued or undervalued?
As of October 17, 2025, DexCom, Inc. is considered overvalued with high valuation ratios and has underperformed in the long term, despite a recent stock return of 2.27%.
DexCom, Inc. Experiences Valuation Adjustment Amidst Competitive Market Landscape
DexCom, Inc. has recently adjusted its valuation, with a current P/E ratio of 64 and a Price to Book Value of 15.03. Compared to peers like Edwards Lifesciences and Agilent Technologies, DexCom's metrics suggest a stronger growth perception. However, its year-to-date performance shows a decline against the S&P 500.
Is DexCom, Inc. overvalued or undervalued?
As of October 17, 2025, DexCom, Inc. is considered overvalued with a valuation grade of "expensive," reflected by a high P/E ratio of 64 and underperformance compared to the S&P 500, with a year-to-date return of -14.36%.
Is DexCom, Inc. overvalued or undervalued?
As of October 17, 2025, DexCom, Inc. is considered expensive and overvalued with a P/E ratio of 64, significantly higher than its peers, and has underperformed the S&P 500 with a year-to-date return of -14.36%.
DexCom, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility
DexCom, Inc. has recently revised its stock evaluation, currently priced at $69.51 after a notable shift. The company has experienced significant volatility over the past year, with a 52-week high of $93.25 and a low of $57.52. Its performance has lagged behind the S&P 500 across various time frames.
DexCom Stock Forms Death Cross, Signaling Potential Bearish Trend Ahead
DexCom, Inc. has recently encountered a Death Cross, indicating a potential shift in market sentiment. The company's daily moving averages are bearish, reflecting a downward trend in price momentum. Over the past year, DexCom has underperformed significantly compared to the S&P 500, with notable declines in various time frames.
Is DexCom, Inc. technically bullish or bearish?
As of September 19, 2025, DexCom, Inc. shows a mildly bearish trend with mixed signals from MACD and moving averages, underperforming the S&P 500 significantly in recent periods.
Is DexCom, Inc. technically bullish or bearish?
As of September 19, 2025, DexCom, Inc. is in a mildly bearish trend, with key indicators signaling bearish momentum, and it has underperformed the S&P 500 with a year-to-date return of -13.27% compared to the S&P 500's 13.31%.
DexCom Stock Hits Day Low of $66.90 Amid Price Pressure
DexCom, Inc. has faced notable stock volatility, with significant declines over various time frames, including a 42.14% drop over the past year. Despite these challenges, the company demonstrates strong operational metrics, including a high return on equity and impressive net sales growth, attracting institutional interest.
Is DexCom, Inc. technically bullish or bearish?
As of September 11, 2025, DexCom, Inc. shows a neutral technical trend with mixed signals, underperforming the S&P 500 year-to-date at -2.56% compared to 12.22%.
Is DexCom, Inc. overvalued or undervalued?
As of May 1, 2025, DexCom, Inc. is considered overvalued with a P/E ratio of 64 and an EV to EBITDA of 39.43, underperforming the S&P 500 with a 1-year return of 9.10% compared to 17.14% and a 5-year decline of 22.14% versus 96.61%.
DexCom Experiences Shift in Technical Trend Amid Strong Financial Performance
DexCom, Inc. has recently experienced a change in its evaluation, indicating a shift in its technical trend. The company showcases strong management efficiency with a high return on equity and a low debt-to-equity ratio. Its recent financial performance highlights significant growth in net sales and operating cash flow.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
